Cargando…
Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy
The identification of echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) fusion gene in non-small cell lung cancer (NSCLC) has radically changed the treatment of a subset of patients harboring this oncogenic driver. Crizotinib was the first ALK tyrosine kina...
Autores principales: | Santarpia, Mariacarmela, Daffinà, Maria Grazia, D’Aveni, Alessandro, Marabello, Grazia, Liguori, Alessia, Giovannetti, Elisa, Karachaliou, Niki, Gonzalez Cao, Maria, Rosell, Rafael, Altavilla, Giuseppe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503498/ https://www.ncbi.nlm.nih.gov/pubmed/28740365 http://dx.doi.org/10.2147/DDDT.S113500 |
Ejemplares similares
-
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
por: Santarpia, Mariacarmela, et al.
Publicado: (2017) -
Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond
por: Karachaliou, Niki, et al.
Publicado: (2014) -
Tumor immune microenvironment characterization and response to anti-PD-1 therapy
por: Santarpia, Mariacarmela, et al.
Publicado: (2015) -
Mechanisms of resistance to osimertinib
por: Lazzari, Chiara, et al.
Publicado: (2020) -
Human endogenous retroviruses and cancer
por: Gonzalez-Cao, María, et al.
Publicado: (2016)